About FAST

FAST Australia launched in September 2010. Inspired by the mission and energy of FAST in the United States, we are driven to address the lack of research and understanding of Angelman syndrome in Australia. Our combined energies create a powerful force in the search for therapeutic interventions and a cure to treat Angelman syndrome.

In an age where Angelman syndrome therapeutics are being developed globally, FAST is working to ensure communities worldwide are organised and prepared to participate in studies for potential therapeutics. FAST has affiliates in Canada, France, Germany, Italy, Latin America (Argentina, Chile, Colombia), Poland, Spain and the UK.

FAST has a vision of a world where lives are no longer limited by a diagnosis of Angelman syndrome.

The mission of the Foundation for Angelman Syndrome Therapeutics Australia is to improve the quality of life for individuals with Angelman syndrome through timely diagnosis, access to best practices in care and treatments, and advancing research for a cure.

Governance

FAST Australia is overseen by a Board of Directors who work with a Chief Executive Officer to utilise their expertise in various fields to advance our mission, assess our strategies and create opportunities to pursue our goals. Our science is vetted by a Scientific Advisory Board (or SAB) consisting of recognised clinicians and scientists considered experts in their respective fields